MedTrace Logo

Escitalopram and Language Intervention for Subacute Aphasia

NCT03843463 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2025-09-23

No results posted yet for this study

Summary

In this project, the investigators will investigate the effects of a selective serotonin reuptake inhibitor (SSRI), escitalopram, on augmenting language therapy effectiveness, as measured by naming untrained pictures and describing pictures, in individuals with aphasia in the acute and subacute post stroke period (i.e., within three months post stroke).

Conditions

Interventions

DRUG

Escitalopram 10mg

Escitalopram tablet

DRUG

Placebo

Sugar pill manufactured to mimic escitalopram 10 mg tablet

BEHAVIORAL

Computer-delivered naming treatment

15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke

Sponsors & Collaborators

  • University of South Carolina

    collaborator OTHER

  • Medical University of South Carolina

    collaborator OTHER

  • University of California, Irvine

    collaborator OTHER

  • National Institute on Deafness and Other Communication Disorders (NIDCD)

    collaborator NIH

  • Johns Hopkins University

    lead OTHER

Principal Investigators

  • Argye Hillis-Trupe, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-18
Primary Completion
2026-09-18
Completion
2027-01-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03843463 on ClinicalTrials.gov